Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Continuing a string of acquisitions, Cambrex has agreed to acquire Avista Pharma Solutions for $252 million. Avista is owned by Ampersand Capital Partners and operates three facilities in the U.S. and one in Scotland. It engages in a range of pharmaceutical services, including early-stage small-molecule development and testing as well as finished-dosage services. The deal follows Cambrex’s acquisition of Halo Pharma earlier this year, which added final-dosage services to Cambrex’s offerings.
This article has been sent to the following recipient: